Loading...
Market
Story
FDA Authorizes Novavax's Updated COVID-19 Vaccine for JN.1 Strain, Age 12 and Older
Aug 30, 2024, 06:51 PM
The U.S. Food and Drug Administration (FDA) has authorized an updated version of the Novavax COVID-19 vaccine for emergency use. This updated 2024-2025 Formula vaccine targets the currently circulating variants, specifically the JN.1 strain, and is intended to provide better protection against serious consequences of COVID-19, including hospitalization and death. It is authorized for individuals aged 12 and older. The approval comes a week after the FDA authorized updated mRNA vaccines from Moderna and Pfizer for the KP.2 variant. The Novavax vaccine offers a protein-based immunization option and is expected to be available in pre-filled syringes across the U.S. in the coming days.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Yes • 50%
No • 50%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Pfizer is perceived as most effective • 25%
Moderna is perceived as most effective • 25%
Novavax is perceived as most effective • 25%
No clear leader in perception • 25%
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
High (>70%) • 25%
Moderate (50-70%) • 25%
Low (30-50%) • 25%
Very Low (<30%) • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
mRNA vaccines • 25%
Non-mRNA vaccines • 25%
No specific recommendation • 25%
Other vaccine types • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%